Literature DB >> 7020042

Immune responses to pneumococcal polysaccharide antigens: a comparison of the murine model and the response in humans.

G Schiffman.   

Abstract

The immune response to pneumococcal polysaccharide antigens has been studied both in mice and, to a lesser extent, in humans. Although there are differences in the immune responses of these two organisms, several major points of similarity have emerged. In both cases the role of the spleen is of importance in mounting an immune response. In both species the presence of certain malignancies causes profound immunosuppression, and treatment of malignancies with radiation and/or cytotoxic drugs results in severe impairment of the host's ability to respond to an immunogenic stimulus and to continue biosynthesis of the specific antibody.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7020042     DOI: 10.1093/clinids/3.2.224

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  4 in total

1.  Laboratory evaluation of five assay methods for vancomycin: bioassay, high-pressure liquid chromatography, fluorescence polarization immunoassay, radioimmunoassay, and fluorescence immunoassay.

Authors:  M A Pfaller; D J Krogstad; G G Granich; P R Murray
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

2.  Alanine aminopeptidase and beta 2-microglobulin excretion in patients receiving vancomycin and gentamicin.

Authors:  M J Rybak; J J Frankowski; D J Edwards; L M Albrecht
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

3.  Epstein-Barr virus induced pneumococcal antibody production in man. A comparison of different lymphoid organs.

Authors:  A Freijd; A Rosén
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

4.  Natural killer cell regulation of age-related and type-specific variations in antibody responses to pneumococcal polysaccharides.

Authors:  M Khater; J Macai; C Genyea; J Kaplan
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.